Author: Ravi Shankar

TORONTO, Oct. 23, 2026 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) today announced the October 2026 cash distributions for AGF Enhanced U.S. Equity Income Fund*, AGF Enhanced U.S. Income Plus Fund*, AGF Total Return Bond Fund* and AGF Systematic Global Infrastructure ETF, which pay monthly distributions. Unitholders of record on October 30, 2026 will receive cash distributions payable on November 5, 2026.

Details regarding the final “per unit” distribution amounts are as follows:

ETF	Ticker	Exchange	Cash Distribution Per Unit ($)
AGF Enhanced U.S. Equity Income Fund*	AENU	Cboe Canada Inc.	$0.199993
AGF Enhanced U.S. Income Plus Fund*	AENP	Toronto Stock Exchange	$0.210357
AGF Total Return Bond Fund*	ATRB	Cboe Canada Inc.	$0.113000
AGF Systematic Global Infrastructure ETF	QIF	Cboe Canada Inc.	$0.158880

*AGF Enhanced U.S. Equity Income Fund, AGF Enhanced U.S. Income Plus Fund and AGF Total Return Bond Fund are mutual funds with an ETF series option.

Further information about the AGF ETFs can be found at AGF.com.

This information is not intended to provide legal, accounting, tax, investment, financial, or other advice, and should not be relied upon for providing such advice. Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated. AGF ETFs are ETFs offered by AGF Investments Inc. ETFs are listed and traded on organized Canadian exchanges and may only be bought and sold through licensed dealers.

The distribution is not guaranteed, may be adjusted from time to time at the discretion of the fund manager and may vary from payment to payment. The payment of distributions should not be confused with a fund’s performance, rate of return or yield. If distributions paid by the fund are greater than the performance of the fund, the original investment will shrink. Distributions paid as a result of capital gains realized by a fund, and income and dividends earned by a fund, are taxable to the investor in the year they are paid. The adjusted cost base will be reduced by the amount of any returns of capital. If the adjusted cost base falls below zero, the investor will have to pay capital gains tax on the amount below zero.

About AGF Management Limited

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. Our companies deliver excellence in investing in the public and private markets through three business lines: AGF Investments, AGF Capital Partners and AGF Private Wealth.

AGF brings a disciplined approach, focused on incorporating sound, responsible and sustainable corporate practices. The firm’s collective investment expertise, driven by its fundamental, quantitative and alternative investing capabilities, extends globally to a wide range of clients, from financial advisors and their clients to high-net worth and institutional investors including pension plans, corporate plans, sovereign wealth funds, endowments and foundations.

Headquartered in Toronto, Canada, AGF has investment operations and client servicing teams on the ground in North America and Europe. With over $75 billion in total assets under management and fee-earning assets, AGF serves more than 820,000 investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

About AGF Investments

AGF Investments is a group of wholly owned subsidiaries of AGF Management Limited, a Canadian reporting issuer. The subsidiaries included in AGF Investments are AGF Investments Inc. (AGFI), AGF Investments LLC (AGFUS) and AGF International Advisors Company Limited (AGFIA). The term AGF Investments may refer to one or more of these subsidiaries or to all of them jointly. This term is used for convenience and does not precisely describe any of the separate companies, each of which manages its own affairs.

AGF Investments entities only provide investment advisory services or offers investment funds in the jurisdiction where such firm and/or product is registered or authorized to provide such services.

AGF Investments Inc. is a wholly-owned subsidiary of AGF Management Limited and conducts the management and advisory of mutual funds in Canada.

Media Contact

Amanda Marchment
Director, Corporate Communications
416-865-4160
amanda.marchment@agf.com

Series	RIKS 37 0115			RIKS 50 0915
Settlement Date	10/28/2026			10/28/2026
Total Amount Allocated (MM)	3,783			3,065
All Bids Awarded At (Price / Yield)	83.810	/	2.848	113.000	/	2.750
Total Number of Bids Received	13			14
Total Amount of All Bids Received (MM)	4,283			3,315
Total Number of Successful Bids	10			11
Number of Bids Allocated in Full	10			11
Lowest Price / Highest Yield Allocated	83.810	/	2.848	113.000	/	2.750
Highest Price / Lowest Yield Allocated	84.036	/	2.820	113.565	/	2.720
Lowest Price / Highest Yield Allocated in Full	83.810	/	2.848	113.000	/	2.750
Weighted Average of Successful Bids (Price/Yield)	83.928	/	2.834	113.269	/	2.736
Best Bid (Price / Yield)	84.036	/	2.820	113.565	/	2.720
Worst Bid (Price / Yield)	83.640	/	2.870	112.560	/	2.774
Weighted Average of All Bids Received (Price / Yield)	83.898	/	2.837	113.228	/	2.738
Percentage Partial Allocation (Approximate)	100.00 %			100.00 %
Bid to Cover Ratio	1.13			1.08

Extends Exchange Election Deadline to November 15 to Facilitate Canadian Shareholder Participation

VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (CSE: HG) (OTCQB: HGRAF) (“HydroGraph” or the “Company”) today reminded its Canadian shareholders of the steps required to defer Canadian capital gains tax in connection with its proposed corporate redomicile transactions (the “Redomicile Transactions”).

Extension of deadline for the election option for exchangeable shares

The Company announced that it has extended the election deadline to November 15, 2026 to give shareholders more time to act. The Redomicile Transactions will be considered at the Special Meeting of Securityholders on October 29, 2026.

KEY CANADIAN SHAREHOLDER ACTIONS — SUMMARY

If you hold HydroGraph shares in a registered or tax-exempt account — TFSA, RRSP, RRIF, LIRA, LIF or similar — you do not need to do anything in respect of these particular shares. These accounts are exempt of capital gains tax and are not eligible for Exchangeable Shares.

If you are a Canadian resident and do not hold your shares in a tax-exempt account  — and you want to defer capital gains tax in respect of such shares, there are two steps. Both are required. Completing only one will not achieve the deferral.

Step 1 — Elect to receive Exchangeable Shares by November 15, 2026. Instead of receiving  Hydrograph Inc. “New U.S. Parent” common stock, you can elect to receive Exchangeable Shares of HydroGraph ExchangeCo Ltd. How you make this election depends on how you hold your shares (see below). The deadline is 5:00 p.m. (Vancouver time) on November 15, 2026 — but your broker’s internal cut-off is earlier, so contact them now.

Step 2 — File the joint tax election in 2027. If you elect Exchangeable Shares, you must also submit the information needed for a joint tax election under subsection 85(1) or 85(2) of the Income Tax Act (Canada) (and, if applicable to you, the applicable provisions of the Taxation Act (Quebec)). The information for the completion of the election forms will be submitted by you through a dedicated portal on the Company’s website.  You will be advised of the date on which you can start submitting that information and the applicable deadline in 2027.

If you do nothing: You will automatically receive Hydrograph Inc. “New U.S. Parent” common stock. This is treated as a “Deemed Election” and is a fully taxable transaction for Canadian federal income tax purposes.

Shareholders should consult their own financial, legal and tax advisors before deciding.

HOW TO MAKE THE ELECTION

If you hold shares through a broker or bank (most shareholders)

The large majority of HydroGraph shareholders hold their shares beneficially through a broker, bank, trust company or other financial intermediary. If that is you and you want Exchangeable Shares, contact your broker or intermediary immediately and instruct them to submit the Letter of Transmittal and Consideration Election Form on your behalf.

If you have not received those instructions from your broker, contact your broker directly. Brokers set their own internal deadlines, which are significantly earlier than the Company’s extended November 15,2026 deadline. Follow your broker’s instructions exactly.

If you are a registered shareholder

Complete, sign and return the Letter of Transmittal and Consideration Election Form, together with any physical share certificates, to the Depositary, Endeavor Trust Corporation. The form must be received by Endeavor Trust Corporation no later than 5:00 p.m. (Vancouver time) on November 15, 2026.

MORE ON THE JOINT TAX ELECTION

Electing Exchangeable Shares is only the first half of the tax deferral. To actually defer the Canadian income tax on capital gains that would otherwise arise on the disposition of your HydroGraph Common Shares, you must also complete a joint tax election under subsection 85(1) or 85(2) of the Income Tax Act (Canada) (and, if applicable to you, the applicable provisions of the Taxation Act (Quebec)).  The information for the completion of the election forms will be submitted by you through a dedicated portal on the Company’s website.  You will be advised of the date on which you can start submitting that information and the applicable deadline in 2027.

Full details of the election and the tax consequences are set out in the Management Information Circular dated September 16, 2026.

KEY DATES

October 29, 2026 — Special Meeting of Securityholders.

November 15, 2026, 5:00 p.m. (Vancouver time) — Deadline to elect Exchangeable Shares. Broker deadlines are earlier.

QUESTIONS

For questions about the Exchangeable Share election or the joint tax election process, contact HydroGraph’s strategic advisor and Information Agent:

Apollo Nora Advisors Ltd.
North American Toll-Free: 1-888-610-4478
Direct Dial: 647-407-5667
Email: info@apollo-advisors.ca

For questions about completing or submitting the Letter of Transmittal, contact the Depositary:

Endeavor Trust Corporation
Telephone: 1-604-559-8880
Email: admin@endeavortrust.com

About HydroGraph
HydroGraph is a leading producer of pristine synthetic graphene using its proprietary Hyperion Reactor technology, which allows for exceptional purity, low energy use, and identical batches. The quality, performance, and consistency of HydroGraph’s graphene follow the Graphene Council’s Verified Graphene Producer® standards, which very few graphene producers are able to meet. For more information or to learn about the HydroGraph story, visit: https://hydrograph.com/. For company updates, please follow HydroGraph on LinkedIn at https://www.linkedin.com/company/hydrograph/ and X at https://x.com/HydroGraphInc.

Trademarks: HydroGraph™, Fractal Graphene™ and Fractal Graphene Paste™

Forward-Looking Statements

This release contains certain “forward-looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “upon”, “anticipate”, “believe”, “continue”, “plans”, “could”, “would”, “should”, “suggests”, “target”, “has the potential to”, “goal”, “on track” or similar terminology. Forward-looking statements in this release include, but are not limited to, the timing of the proposed Redomicile Transactions; and the receipt of required securityholder, court and other approvals in connection therewith.

Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable, and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of HydroGraph to control or predict, that may cause HydroGraph’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: HydroGraph’s ability to implement its business strategies; the ability to obtain securityholder, court and other approvals required for the redomicile; delays in permitting, construction, commissioning or operation of production facilities; the availability and reliability of feedstock supply; the pace of customer qualification and adoption of graphene products; the risk that commercial negotiations do not result in binding agreements or do not close within the expected timeframe; the risk that anticipated purchase orders, supply agreements or commercial relationships are not obtained on the expected timeline or at all; the Company’s dependence on U.S. government funding, procurement cycles, appropriations and security and export control requirements in connection with its defense initiatives; the extended development cycles associated with defense research programs; risks relating to the establishment and development of a U.S.-based graphene innovation organization; risks associated with general economic conditions; adverse industry events; stakeholder engagement; marketing and transportation costs; loss of markets; volatility of commodity prices; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; industry and government regulation; changes in legislation, income tax and regulatory matters; competition; currency and interest rate fluctuations; and other risks. HydroGraph does not undertake any obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CONTACTS:
Matt Kreps
Senior Vice President of Capital Markets and Investor Relations
+1-214-597-8200
matt.kreps@hydrograph.com

• Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the BriaCell regimen
• Findings from a prospective pooled analysis of 111 heavily pretreated metastatic breast cancer patients support further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit from immunotherapies
• Pooled analysis includes patients from multiple studies, including BriaCell’s earlier Phase 1/2 Bria-IMT™ study

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer (“MBC”) treated with immune based therapies including the BriaCell regimen at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place October 23-27, 2026 in Madrid, Spain. The data shown is pooled from several studies including BriaCell’s Phase 1/2 Bria-IMT study.

The analysis evaluated changes in programmed death-ligand 1 (“PD-L1”) expression on circulating cancer-associated macrophage-like cells (“CAMLs”) before and after initiation of immunotherapy and their association with progression-free survival (“PFS”) and overall survival (“OS”). The findings suggest that changes in CAML PD-L1 following treatment may provide information regarding clinical outcomes that are not captured by a single pretreatment measurement.

“We are encouraged by these findings showing that dynamic changes in a circulating immune biomarker were associated with progression-free and overall survival in patients with metastatic breast cancer treated with immunotherapies,” stated Dr. William V. Williams, BriaCell’s President and CEO. “These results support further study of CAML PD-L1 as a potential tool for understanding treatment response and identifying patients most likely to benefit from immunotherapy, including the Bria-IMT regimen.”

Poster #4506 – Monitoring Circulating Cancer Associated Macrophage-like Cell PD-L1 Predicts Clinical Outcomes in Metastatic Breast Cancer Treated with Immune Checkpoint Inhibitors

The prospective, multi-institutional pooled analysis included 111 patients with MBC who had received at least one prior line of therapy and were treated with pembrolizumab, retifanlimab, atezolizumab, or nivolumab. Some also received combination therapy with the Bria-IMT regimen. Patients had a median age of 59 years, with a range of 32 to 77 years, and had received a median of two prior metastatic lines of therapy, with a range of one to 13.

Among the 111 patients, 39% were estrogen receptor-positive, 31% were progesterone receptor-positive, 5% were HER2-positive, and 60% had triple-negative breast cancer.

Peripheral blood samples were collected prior to initiation of immunotherapy, approximately 37 days after initiation of immunotherapy (“T1”), and approximately three months after initiation of immunotherapy (“T2”). CAMLs were isolated from blood samples, and PD-L1 expression was categorized as low or high.

Key findings included:

• At baseline, CAML PD-L1 was not significantly associated with either PFS or OS.
• At T1, approximately 37 days following initiation of immunotherapy, CAML PD-L1 was significantly associated with PFS (HR=1.86; p=0.0276), but not OS (HR=1.28; p=0.5663).
• At T2, approximately three months following initiation of immunotherapy, CAML PD-L1 was significantly associated with both PFS (HR=2.73; p=0.0028) and OS (HR=2.27; p=0.0420).
• Pretreatment tumor PD-L1 combined positive score (“CPS”) of 10 or greater was not significantly associated with improved PFS or OS in the pooled population.

“These findings suggest that monitoring dynamic PD-L1 changes in circulating tumor-associated immune cells following initiation of immunotherapy may provide information regarding clinical benefit in patients with MBC and are consistent with findings reported in the Bria-IMT Phase 2 study,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “Further studies are needed to validate CAML PD-L1 as a predictive biomarker.”

About BriaCell’s Pivotal Phase 3 Clinical Study of Bria-IMT Combination Regimen in MBC patients

BriaCell’s pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer is ongoing.

The study’s primary endpoint is overall survival, comparing patients treated with the Bria-IMT combination regimen with patients receiving physician’s choice treatment. The planned interim analysis will be conducted following 144 patient deaths. Positive results from the pivotal Phase 3 study could support a potential application for marketing approval of Bria-IMT in metastatic breast cancer. BriaCell reported positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track designation.

For additional information on BriaCell’s pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov NCT06072612.

A copy of the poster presentation is available at https://briacell.com/scientific-publications/.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the presentation of clinical data at the ESMO Congress 2026, and the contents of all such presentations, the early constructive clinical biomarker data allowing the Company to predict clinical and survival outcomes and guide treatment decisions for metastatic breast cancer patients, and the Company’s anticipated timing of analysis of interim data, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

• Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone¹
• Benefit increased over time in invasive disease-free survival and across key secondary endpoints^1-3
• Patients off Kisqali for a median of three years, with clinical benefit continuing to deepen after treatment completion^1-3 

Basel, October 23, 2026 – Novartis today announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival (OS) data with Kisqali^® (ribociclib) plus endocrine therapy (ET) compared to ET alone¹. The study was in the broadest early breast cancer (eBC) population of patients with stage II and III HR+/HER2- early breast cancer at high risk of recurrence, including those with high-risk node-negative (N0) disease and all node-positive patients^1,2. Kisqali plus ET reduced the risk of death by nearly 20% (19.1%) compared to ET alone (HR=0.809; 95% CI: 0.661-0.989), with consistent overall survival benefit observed across all key subgroups¹. These late-breaking results will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2026.

Patients have been off Kisqali for a median of three years (38 months) and have passed the five-year protocol-specified ET duration^1,2. The invasive disease-free survival (iDFS) benefit increased from 4.1% at five years to 5.3% at six years, underscoring the long-term value of dual inhibition, with benefit observed years after treatment completion^1,3.

Fewer patients treated with Kisqali plus ET experienced metastatic recurrence compared to ET alone, and OS continued to increase over time, with the absolute difference increasing from 1.2% at five years to 2.1% at six years^1,3. Breast-cancer specific survival (BCSS) was supportive of OS benefit, showing a ~30% reduction in risk of breast cancer-specific deaths (HR=0.709; 95% CI: 0.559-0.890) compared to ET alone¹.

Six-year NATALEE results reinforce long-term clinical benefit
“The NATALEE six-year data clearly demonstrate a clinically meaningful improvement in overall survival with ribociclib plus endocrine therapy,” said Dennis J. Slamon, MD, Chief of the Division of Hematology/Oncology, UCLA Department of Medicine. “These findings have very important implications for patients as well as health care providers worldwide and further strengthen the role of ribociclib in treating patients with HR+/HER2- early breast cancer at high risk of recurrence.”

Benefits observed across major efficacy endpoints, with sustained or increasing improvements over six years^1,3.

Endpoint	Hazard Ratio	95% CI	Absolute Benefit at 5Y	Absolute Benefit at 6Y
Overall Survival (OS)	0.809	0.661-0.989	1.2%	2.1%
Breast-Cancer Specific Survival (BCSS)	0.709	0.559-0.890	1.5%	2.6%
Invasive Disease-Free Survival (iDFS)	0.741	0.646-0.849	4.1%	5.3%
Distant Disease-Free Survival (DDFS)	0.744	0.646-0.858	3.7%	4.9%
Distant Recurrence-Free Survival (DRFS)	0.738	0.631-0.846	3.5%	4.4%

“The clinically meaningful overall survival benefit observed in NATALEE underscores Kisqali as a standard of care for eligible patients and its foundational role in early breast cancer treatment,” said Andrea Myers, Global Head, Oncology Development, Novartis, Ad Interim. “These findings demonstrate the value of combining CDK4/6i with endocrine therapy in the broadest population of patients at high risk of recurrence, including those with high-risk node-negative disease and all node-positive patients.”

With longer follow-up, the safety profile remained consistent with previous analyses, and no new safety signals were observed^1-3. Overall, rates of secondary primary malignancies (SPMs) were 3.0% with Kisqali plus ET and 3.3% with ET alone¹. SPMs leading to death were 0.2% in both the Kisqali plus ET and ET alone arms¹.

Building on established Kisqali overall survival evidence
Kisqali is the only CDK4/6 inhibitor to demonstrate statistically significant OS benefit across three randomized controlled trials (MONALEESA-2, MONALEESA-3, and MONALEESA-7) in metastatic breast cancer and clinically meaningful OS in the broadest early breast cancer population at high risk of recurrence, including node-negative and node-positive disease^1,4-14.

“For those diagnosed with early breast cancer who face a higher risk of recurrence, having meaningful long-term overall survival data is invaluable,” said Jean A. Sachs, Chief Executive Officer, Living Beyond Breast Cancer. “These new insights help with important, shared decision-making conversations with their medical team, and make clear the importance of continued research to support those navigating complex decisions.”

About NATALEE
NATALEE is a global Phase III, multi-center, randomized, open-label trial to evaluate the efficacy and safety of Kisqali with ET as an adjuvant treatment versus ET alone in the broadest range of patients with stage II and III HR+/HER2- eBC, being conducted in collaboration with TRIO^15,16. The adjuvant ET in both treatment arms was a non-steroidal aromatase inhibitor (NSAI; anastrozole or letrozole) and goserelin, if applicable^15,16. The primary endpoint of NATALEE is invasive disease-free survival (iDFS) as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria^15,16. A total of 5,101 adult patients with HR+/HER2- eBC across 20 countries were randomized in the trial^15,16.

About Kisqali^® (ribociclib)
Kisqali^® (ribociclib) is a selective cyclin-dependent kinase inhibitor, helping slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, enable cancer cells to grow and divide quickly. Targeting CDK4/6 with enhanced precision plays a role in tumor control.

Kisqali has been approved as a treatment for breast cancer by regulatory authorities in more than 100 countries worldwide, including the US FDA and the European Commission^16,17. In the US, Kisqali is indicated in combination with an AI as an adjuvant treatment for adults with HR+/HER2- stage II and III eBC at high risk of recurrence, as well as for the treatment of adults with HR+/HER2- advanced or metastatic breast cancer (mBC) as initial ET; Kisqali is also approved in the metastatic setting in combination with fulvestrant as initial ET or following disease progression on ET¹⁶. In the EU, Kisqali is approved in combination with an AI for the adjuvant treatment of patients with HR+/HER2- eBC at high risk of recurrence; and for the treatment of women with HR+/HER2- locally advanced or mBC in combination with either an AI or fulvestrant as initial ET or following disease progression who have prior endocrine therapy¹⁷. In pre- or peri-menopausal women, the ET should be combined with a luteinizing hormone-releasing hormone agonist^16,17.

In EBC, Kisqali is the only CDK4/6 inhibitor recommended by the NCCN Guidelines® for breast cancer as Category 1 preferred for both all node-positive disease as well as for patients with no nodal involvement with high-risk disease characteristics, such as tumor size >5 cm, or for tumors sized 2-5 cm, either Grade 2 with high genomic risk/Ki-67 ≥20% or Grade 3¹⁸. Kisqali approvals in eBC from regulatory authorities worldwide are ongoing, including recent approval from China’s National Medical Products Administration¹⁹. In mBC, Kisqali has consistently demonstrated statistically significant overall survival benefit across three Phase III trials^4-14. The NCCN Guidelines® also recommend Kisqali as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of people living with HR+/HER2- MBC when combined with an AI, making Kisqali the preferred first-line treatment of choice for US prescribers in HR+/HER2- mBC¹⁸.

In addition, Kisqali has achieved the highest score (A) on the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) for eBC; and has the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale, achieving a score of four out of five for first-line pre-menopausal patients with HR+/HER2- advanced breast cancer^20,21. Further, Kisqali in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four out of five for post-menopausal patients with HR+/HER2- advanced breast cancer treated in the first line²².

Kisqali was developed by Novartis under a research collaboration with Astex Pharmaceuticals.

About Novartis in Breast Cancer
For more than 30 years, Novartis has been at the forefront of driving scientific advancements for people touched by breast cancer and improving clinical practice in collaboration with the global community. With one of the most comprehensive breast cancer portfolios and pipeline, Novartis is an industry leader in the discovery of new therapies and combinations in HR+/HER2- breast cancer, the most common form of the disease.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. Slamon D et al. Adjuvant ribociclib + nonsteroidal aromatase inhibitor in patients with HR+/HER2− early breast cancer:  NATALEE 6-year overall survival and efficacy outcomes. Presented at the European Society of Medical Oncology (ESMO) Congress. October 23-27, 2026. Madrid, Spain.
2. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080-1091. doi:10.1056/NEJMoa2305488
3. Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant Ribociclib Plus Nonsteroidal Aromatase Inhibitor Therapy in Patients With HR+/HER2− Early Breast Cancer: NATALEE 5-Year Outcomes. Presented at the European Society for Medical Oncology (ESMO) Congress; October 17-21, 2025; Berlin, Germany.
4. Yardley DA et al. Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Poster presented at the European Society of Medical Oncology Congress. September 9-13, 2022. Paris, France.
5. Neven P et al. Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Mini oral presented at the European Society for Medical Oncology Breast Cancer Congress. May 4, 2022. Paris, France.
6. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663.
7. Hortobagyi GN et al. Overall survival (OS) results from the phase III MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. LBA 17. Proffered paper presented at the European Society of Medical Oncology Congress, September 16-21, 2021. Lugano, Switzerland.
8. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316. doi:10.1056/NEJMoa1903765.
9. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149.
10. Slamon DJ et al. Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). LBA7_PR. Presented at the European Society of Medical Oncology Congress. September 29, 2019. Barcelona, Spain.
11. Slamon DJ et al. Updated overall survival (OS) results from the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Presented at the American Society of Clinical Oncology Annual Meeting. June 5, 2021. Chicago, USA.
12. Tripathy D et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at the San Antonio Breast Cancer Symposium. December 9, 2020. Texas, USA.
13. Yardley D et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Presented at the American Society of Clinical Oncology Annual Meeting. June 2020. Chicago, USA.
14. O’Shaughnessy J et al. Overall survival subgroup analysis by metastatic site from the Phase III MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with HR+/HER2− advanced breast cancer. Presented at the San Antonio Breast Cancer Symposium. December 7-10, 2021. Texas, USA.
15. Clinicaltrials.gov. NCT03701334. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/ HER2- Early Breast Cancer (NATALEE). Accessed September 2026. https://clinicaltrials.gov/study/NCT03701334
16. Kisqali. Prescribing Information (US FDA). Novartis Pharmaceuticals Corporation; 2017. Accessed November 2025. https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf
17. Kisqali. Summary of product characteristics (SmPC). Novartis Europharm Limited; 2017. Accessed November 2025. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf
18. NCCN Guidelines. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) РBreast Cancer. Accessed November 2025. https://www.nccn.org
19. National Medical Products Administration. Drug Evaluation Information Disclosure: Drug Evaluation Approval Results. National Medical Products Administration. Published May 21, 2025. Accessed November 2025. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250521151427103.html
20. European Society of Medical Oncology (ESMO). ESMO MCBS scorecards; NATALEE. Available from: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-468-1 Accessed November 2025.
21. European Society for Medical Oncology. Magnitude of Clinical Benefit Scale Scorecard. Updated February 7, 2025. Available from: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1. Accessed November 2025.
22. European Society for Medical Oncology. Magnitude of Clinical Benefit Scale Scorecard. Updated February 7, 2025. Available from: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1. Accessed November 2025.

Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

• Bombardier is expanding its presence across the country, hiring 800 people for jobs located in its home base of Kansas as well as Texas, Indiana, and Connecticut
• This strategy includes an initial phase of investment estimated at $270M earmarked for infrastructure growth
• Bombardier selects Texas as pillar of ongoing Services expansion with 150 high-skilled new jobs planned for the state; expands in Midwest with Fort Wayne, Indiana, Service Center to open in November⁽¹⁾

MONTREAL, Oct. 23, 2026 (GLOBE NEWSWIRE) — Bombardier today announced that it is continuing to significantly enhance its American footprint. The company plans to hire 800 people across America. Today, Bombardier is actively recruiting for 500 positions across the country and plans to create an additional 300 jobs through footprint expansion projects⁽¹⁾. Texas is planned to be the next pillar of expansion and will account for 150 of the 300 new jobs. Hiring activities will further be spread across the company’s U.S. home base in Kansas as well as in Indiana and Connecticut. Job creation in these states will be driven by infrastructure investments, which will total an estimated $270M in the first phase.

“Our American service network is a key pillar of Bombardier’s growth strategy. This new wave of expansion and hiring reflects our long-term confidence in this market and our employees in America,” said Eric Martel, President & CEO, Bombardier. “Based on our constructive conversations with the U.S. administration, we see a bright path forward for our highly skilled aerospace workers as well as a positive environment for Bombardier to continue pursuing direct investments to grow our American footprint.”

Bombardier’s Learning Center in Wichita, Kansas represents one component of Bombardier’s broader investment in this iconic city. Inaugurated last week, the new North American Learning Center reinforces the company’s commitment to developing talent, enhancing capabilities and supporting the long-term growth of its Kansas operations.

Bombardier’s newest American service facility at Fort Wayne International Airport in Fort Wayne, Indiana, is an approximately 64,500-square-foot facility that will accommodate up to six aircraft and offer scheduled and unscheduled maintenance, modifications, avionics installations and AOG support. The company will further launch new footprint expansion projects in Dallas, Texas, and Connecticut.

In 2025, the company’s U.S. activities supported 27,200 American jobs⁽²⁾ throughout its service and manufacturing facilities, as well as within a broad supply chain, where Bombardier spent $2.8 billion. The 27,200 jobs across America, supported by Bombardier activities, carried a 7-to-1 ratio: for every one Bombardier job, activities support seven additional jobs across the economy through supplier purchases and household spending⁽²⁾. Based on current hiring and expansion plans, the total number of jobs supported is projected to exceed 33,000⁽¹⁾.

Bombardier’s American workers are based all around the United States with sites in Kansas, Texas, Arizona, Florida, Connecticut, Illinois, Delaware, California, Washington D.C. and New Jersey, with Bombardier’s overall direct employment presence covering more than 20 states. Bombardier continues to invest in the people, infrastructure and capabilities that support its customers and grow the American aerospace industry.

About Bombardier

At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.

For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.

Bombardier customers operate a fleet of approximately 5,300 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico. In 2024, Bombardier was honoured with the prestigious “Red Dot: Best of the Best” award for Brands and Communication Design.     

For Information

For corporate news and information, including Bombardier’s Sustainability report, as well as the company’s initiative to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book-and-Claim system visit bombardier.com.

Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.

Media Contacts
General media contact webform

Mark Masluch
+1 (514) 855-7167   
mark.masluch@aero.bombardier.com

(1) Forward-looking statements 
This press release contains certain forward-looking statements. By their nature, forward-looking statements require the Corporation to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause actual results in future periods to differ materially from those set forth in the forward-looking statements. Please refer to the “Forward-Looking Statements” disclaimer contained in Bombardier Inc.’s most recently published financial report for additional details.

(2) Oxford Economics study conducted for Bombardier.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0afefc1e-b3ec-492e-bc39-d3befc30c62d

Renk Group AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

23. Oct 2026 / 13:17 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Legal entity

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

• WeRide was named among WICV 2026’s “Top 10 Automotive AI Application Cases of 2026” for its Physical AI flywheel powered by GENESIS and WITT.
• Founder and CEO Dr. Tony Han shared WeRide’s approach to applying L4 autonomous driving technology to L2 advanced driver-assistance systems, emphasizing intelligence density and safety.
• WeRide continues to expand real-world deployment across L2 to L4, with operations in more than 60 cities across 13 countries and an L4 fleet of approximately 3,600 vehicles.

BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, has been named among the “Top 10 Automotive AI Application Cases of 2026” at the 2026 World Intelligent Connected Vehicles Conference (WICV). The recognition highlights WeRide’s innovative Physical AI flywheel powered by WeRide GENESIS and WeRide WITT, demonstrating how the company is translating cutting-edge AI technologies into large-scale commercial applications.

WeRide’s Physical AI flywheel recognised among the “Top 10 Automotive AI Application Cases of 2026”.

The selected case of WeRide’s Physical AI flywheel, highlights the practical application of the collaborative application of cutting-edge AI technologies in autonomous driving development. At its core, the flywheel brings together WeRide GENESIS, WeRide’s proprietary general-purpose simulation model, and WeRide WITT, WeRide’s Physical AI Cognitive Foundation Model. WeRide WITT extracts and validates physical facts from real-world road data, while WeRide GENESIS uses these insights to generate high-fidelity simulation scenarios that adhere to real-world physical laws, strengthening training in complex driving scenarios and long-tail situations. Together, the two models empower vehicle-side models, improve development efficiency and adaptability to complex scenarios, and support the deployment of autonomous driving technology across cities and vehicle platforms.

Focusing on the path to scaled production of autonomous driving, Dr. Tony Han, Founder and CEO of WeRide, delivered a keynote titled “The Critical Leap Toward Scaled Deployment of Autonomous Driving” at the conference’s Key Technology Forum, sharing WeRide’s experience in applying L4 expertise to L2 advanced driver-assistance systems (ADAS).

Dr. Han highlighted “intelligence density” as a key metric for evaluating ADAS solutions: how much intelligence each TOPS of computing power can deliver. The goal is to achieve a higher level of intelligent driving with limited computing resources. He also emphasized that investing in safety is essential to earning user trust and building long-term brand value. As the technology advances and its applications expand, safety must remain a priority at every stage, protecting not only passengers inside the vehicle but also every road user outside it.

WICV 2026 was held in Yizhuang, Beijing, from October 21 to 23, and was co-hosted by China’s Ministry of Industry and Information Technology, Ministry of Transport, and the People’s Government of Beijing Municipality. This year’s conference was themed “Pooling Wisdom, Boundless Connectivity: Advancing Steadily Towards a New Era of Automated Driving”. The conference has been held annually since 2018 and serves as a major industry event for intelligent connected vehicles, as well as an important platform for policy development and international cooperation.

WeRide’s autonomous driving technologies were also showcased in real-world applications during the conference. During WICV 2026, WeRide deployed more than a dozen Robotaxis and Robobuses, providing autonomous ride experiences and shuttle services for attendees. The nearly 7-kilometer Robotaxi experience route started and ended at the main venue, while Robobuses provided shuttle services connecting conference venues and visitor destinations, including Yonghui Building, BAIC BluePark, Rocket Street, and Robot World.

Today, WeRide has commercialized its full-stack autonomous driving technologies spanning L2 to L4, with operations spanning more than 60 cities across 13 countries worldwide. Its L4 autonomous driving fleet comprises approximately 3,600 vehicles, supported by extensive operating experience across different cities and real-world use cases.

WeRide’s autonomous passenger vehicles are already operating publicly in major global cities, including Guangzhou, Beijing, Abu Dhabi, Dubai, Singapore, Riyadh, and Zurich. Through global mobility platforms such as Uber and Grab, as well as local partners including SBB, ioki and TXAI, WeRide is integrating autonomous driving into more urban transportation networks and will soon launch services in additional markets including Spain and Denmark.

WeRide’s L4 autonomous driving technology is also empowering mass-produced passenger vehicles through shared technology architecture. WRD 3.0, WeRide’s one-stage end-to-end L2++ ADAS solution, has been deployed on models including the Chery Exeed Sterra, GAC AION N60, AION i60, and GAC Trumpchi Y7. To date, WRD 3.0 has secured production design wins across more than 30 vehicle models, bringing advanced driving technologies to a broader consumer base.

As the intelligent connected vehicle industry enters a new phase of development, WeRide will continue to advance Physical AI innovation and promote technological synergies across L2 to L4. Working with global industry partners, WeRide will expand the real-world application of its technologies at scale, translating technological progress into safer and more reliable mobility experiences.

About WeRide

WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been deployed in over 60 cities across 13 countries. We are also the first and only technology company whose products have received autonomous driving permits in nine markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, Spain, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune’s Change the World lists in 2023, 2025, and 2026, and to the Fortune Future 50 list in 2025.

Media Contact

pr@weride.ai

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dd7a36dc-21e5-4ca6-a522-9e2ab4a4a2f3

Voluntary Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing

TEL AVIV, Israel, Oct. 23, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX) (“Gix” or the “Company”), a dual-listed technology company, today announced that it has initiated a process to voluntarily delist its ordinary shares, no par value per share, from the Tel Aviv Stock Exchange Ltd. (the “TASE”).

In accordance with applicable Israeli law and the rules of the TASE, the last day the ordinary shares will trade on the TASE is expected to be January 25, 2027, and the ordinary shares are expected to be delisted from the TASE on or about January 27, 2027. Shareholders will be able to continue to buy and sell ordinary shares on the TASE in the same manner as has been the case to date until market close on the final day of trading.

The Company’s ordinary shares will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GIXI,” and the Company will also continue to file public reports and disclosures in accordance with the rules and regulations promulgated by the U.S. Securities and Exchange Commission (“SEC”) and Nasdaq. The delisting from the TASE will not affect Gix’s continued listing on Nasdaq in the United States, and all ordinary shares currently traded on the TASE may be transferred to Nasdaq.

The Company’s Board of Directors approved the delisting of the ordinary shares from the TASE and a transition to exclusive trading on Nasdaq with the objective of potentially enhancing liquidity on Nasdaq, and allowing the Company to focus its investor and public relations efforts on the U.S. capital markets.

About Gix Internet Ltd.

Gix Internet Ltd. is a technology company that is listed on the Nasdaq Capital Market under the symbol GIXI and on the Tel Aviv Stock Exchange under the symbol GIX. Its operating focus is Deliverz.ai, a wholly-owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

About deliverz.ai

deliverz.ai is defining the future of healthcare logistics automation with an end-to-end, AI-powered orchestration platform that unifies autonomous robots, human transport teams, and hospital workflows into a single intelligent system. Robot-agnostic and built to scale, deliverz.ai automates and optimizes logistics across any workflow and within any environment, increasing throughput, reducing costs, and improving both patient and staff experience. Delivered through a flexible Software as a Service (SaaS) and Robotics as a Service (RaaS) model, deliverz.ai provides the intelligent logistics backbone for hospitals, making operations smarter, faster, and patient-centered. For more information, visit https://www.deliverz.ai

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the voluntary delisting of its ordinary shares from the TASE, including the expected timing of the last trading day and of the delisting; the continued trading of its ordinary shares on Nasdaq; and the expected benefits of the delisting and of exclusive trading on Nasdaq, including potentially enhancing liquidity on Nasdaq and focusing its investor and public relations efforts on the U.S. capital markets. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

Transaction in Own Shares

October 22, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 22 October 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
22/10/2026	1,075,000	£ 39.7050	£ 38.8900	£ 39.3207	LSE	GBP
22/10/2026	–	–	–	–	Chi-X (CXE)	GBP
22/10/2026	–	–	–	–	BATS (BXE)	GBP
22/10/2026	535,000	€ 47.6000	€ 46.5900	€ 47.1506	XAMS	EUR
22/10/2026	–	–	–	–	CBOE DXE	EUR
22/10/2026	–	–	–	–	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

• 20261022_Shell RNS – full version